National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
NCT Number: NCT02338986
Background:
- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of these diseases don t have good treatments available. Researchers may be able to develop a treatment by using antibodies against these infections.
Objective:
- To collect antibodies from people with high levels of antibodies to the diseases being studied.
Eligibility:
- Ages 18-70 years old who weigh at least 110 pounds. They may have been infected with or vaccinated for one of the new infections researchers are studying.
Design:
* Participants will be screened with medical history and blood tests. Researchers will determine if the participant can have apheresis. * Participants will have apheresis. First, they will be interviewed. Then, a needle will be placed in a vein. Blood will be drawn, and a machine will separate the blood cells from the antibodies and protein. The blood cells will then be returned to the participant through another vein. It takes about 60 minutes for the actual collection. * Participants will be asked to have the procedure at least 3 times. They can participate in up to 20 sessions total as part of this study. There must be at least 7 days between sessions.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Bethesda, Maryland, 20892, United States
The administration of convalescent plasma is often used for treatment of emerging infectious diseases. This natural history protocol will collect plasma from subjects that were vaccinated to or recovered from an emerging infectious disease of interest, in a manner that the plasma can be given to other subjects as a therapeutic. Any administration of plasma to subjects will be under a separate protocol.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Exclusion criteria
to:
Plasma
Time frame: 5 years after enrollment
The number of units of human plasma collected from volunteers with high titer antibodies for a given emerging infectious disease, that is potentially suitable for infusion into humans as part of a separate treatment study.
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03931941
Bacterial Infections, Bacterial Infections and Mycoses
Phoenix, Arizona, United States
View Trial DetailsNCT02046512
Anti-Infective Agents, Communicable Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06164600
Child, Communicable Diseases
Cairo, Abbasseiya, Egypt
View Trial DetailsNCT06112249
Communicable Diseases, Disease Attributes
Collingswood, New Jersey, United States
View Trial Details